anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
With high prevalence and substantial mortality, metabolic dysfunction-associated steatotic liver disease and chronic obstructive pulmonary disease (COPD) are significant public health concerns. Utilizing a large, population-based dataset from the National Health and Nutrition Examination Survey, our study probes the relationship between COPD prevalence and hepatic steatosis and fibrosis, as measured by Vibration-Controlled Transient Elastography. We analyzed data from 693 individuals with COPD and 7229 without. Through weighted multivariate logistic regression analysis, a restricted cubic spline curve, and threshold effect analysis, we investigated the correlation between the severity of hepatic steatosis and fibrosis and the presence of COPD. Our findings revealed a positive correlation between the controlled attenuation parameter (CAP) and COPD prevalence [OR = 1.03 (95% CI 1.01, 1.05)], even after multivariate adjustment. Furthermore, we observed a U-shaped association between CAP and COPD, where the inflection point, CAP value of 264.85 dB/m, corresponded to the lowest COPD prevalence. Our study emphasizes a substantial and complex link between hepatic steatosis and COPD. These findings urge healthcare professionals to factor liver health into COPD management and prompt further exploration into the underlying mechanisms. This could pave the way for the development of improved prevention and treatment strategies.
Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
In controlled clinical trials for the management of acne vulgaris, the occurrence of adverse reactions associated with the use of Sodium Sulfacetamide Lotion was infrequent and restricted to local events. The total incidence of adverse reactions reported in these studies was less than 2%. Only one of 105 patients treated with Sodium Sulfacetamide Lotion had adverse reactions of erythema, itching, and edema. It has been reported that sodium sulfacetamide may cause local irritation, stinging, and burning. While the irritation may be transient, occasionally the use of medication has to be discontinued.

To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
A mixt. of calcium hydroxide and oleum pedum tauri and opt. pharmaceutically acceptable auxiliaries can be used to form new collagen in vivo in traction in cases of bone trauma. The vol. ratio calcium hydroxide/oleum pedum is 2/1-1/2 esp. 1/1. The mixt. can also contain barium sulphate and/or white vaseline. USE/ADVANTAGE - The mixt. promotes the formation of new collagen in vivo and can be used in general surgery, jawbone surgery, orthopaedics, implantology, traumatology, etc. and in bone trauma such as fractures, wells, cavities etc. No details given in body of specification. Collagen regeneration is rapid. There is on problem if excess mixt. is used as it is either pressed out when fixing agent is applied, or diffuses in the ispogiosa. The mixt. also counters inflammation. In an example 7 holes were bored in the upper jaw of a 50 year old toothless patient in order to place false teeth. The holes were 1.5-2 cm deep and 3 mm wide. Before screwing in the implants the holes were filled with the mixt. of the invention. The next day, the patient needed to take no tablets for pain relief and the swelling was minimal. After 2 weeks X rays showed that the expected reactive osteolysin rings around the implants were completely absent. This meant that, even after 2 weeks, osteointegration of the implants was detected; this is normally to be expected 5-6 months later. The X-ray picture after 2 weeks was 90% of that usually expected after 6 months.
Hepatocellular carcinoma (HCC) is a complex disease associated with a plethora of environmental and genetic/hereditary causative risk factors, more so than other oncological indications. Additionally, patients with HCC exhibit fibrosis, cirrhosis, and liver-related disease. This complicated etiology can affect the disease course and likely contributes to its poor prognosis. In this study, we aimed to improve HCC therapy by evaluating combination treatment using anti-cancer and anti-fibrosis drugs via identification of novel anti-fibrosis drugs. We performed high-throughput screening of 10,000 compounds to identify hepatic fibrosis inhibitors through morphometry analysis of multicellular hepatic spheroid (MCHS) models and identified CHIR-99021 as a candidate anti-fibrotic drug. Treatment with CHIR-99021 induced loss of cell-cell interactions and suppression of extracellular matrix-related protein expression via reprogramming of hepatic stellate cell (HSC) activation in MCHSs. In particular, CHIR-99021 regulated DNMT3B expression only in activated HSCs. Moreover, CHIR-99021 markedly improved the efficacy of sorafenib in HCC- multicellular tumor spheroids in vitro and through induction of apoptosis by decreasing DNMT3B expression in vivo. In summary, these findings suggest that targeting HSC reprogramming by attenuation of DNMT3B expression in the tumor environment might represent a promising therapeutic strategy for liver fibrosis and HCC.
INTRODUCTION: Autologous fat transfer (AFT) is widely used to improve results of breast reconstructive surgery, but its safety is controversial. Our objective was to evaluate the oncologic safety of AFT in a homogeneous population of patients who underwent a total mastectomy with immediate reconstruction for breast cancer.
METHODS: We performed a retrospective cohort study by identifying all patients who underwent immediate breast reconstruction after mastectomy for breast cancer from 2007 to 2015 in our center. A patient group with AFT performed in the 24 months after mastectomy was compared to a control group.
RESULTS: Five hundred fifty cases were included, of whom 136 (24.7%) underwent at least one fat graft transfer. Median age was 51 years. Reconstruction was performed in 465 (84.5%) with an implant reconstruction. The median time from mastectomy to AFT was 13.8 months. The median follow up was 55.2 months. A total of 53 events were observed, including 10 (7.4%) in the AFT group and 43 (10.4%) in the control group. There was no difference in 5-year recurrence-free survival (RFS) between the groups. In the subgroup analysis, only lymph node involvement in patients who underwent AFT in the first 24 months after oncologic surgery appeared as a risk factor of recurrence. Among the 104 patients with lymph node involvement, 5-year RFS was 69.2% in patients with lipofilling vs 92.5% in patients without it (p = 0 0.0351).
CONCLUSION: Performing early lipofilling in primary breast reconstruction after mastectomy for cancer seems to be oncologically safe. Lymph node involvement increases the risk of recurrence in this population.
The experimental product contains 9mg (18mg/day) of lipid soluble pollen extract fraction. Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit. If a dose is missed participants are instructed to take the missed dose with the next scheduled dose. Participants will be advised not to exceed 3 capsules daily.
When a patient comes with intra oral sinus tract will treat in a single visit. The treatment protocol will be: cleaning and shaping by NITI file ( pro taper gold ) with Naocl 5.25%, EDTA 17% and saline then the canal will be obturate by single cone technique with bioceramic sealer.
The invention provides a preparation method of deslanoside injection. According to the preparation method, the temperature of water for injection of liquor is lowered to 35-42 DEG C, heat treatment is carried out at 100 DEG C for 30 minutes or is not adopted, and ethanol (re-steaming) is changed into ethanol (medicinal) and is directly used without re-steaming, so that the re-steaming time and cost are saved, and the quality can be ensured. According to an experimental study, the related substance indexes of the product prepared by the method are obviously reduced, the product quality is improved, and the product risk is lowered. A complete inspection according to the standard of Chinese Pharmacopoeia 2010 shows that all indexes of the deslanoside injection produced by the new method meet the standard requirements. The preparation method is simple, the product quality is ensured without increasing new cost, and the cost and energy consumption can be lowered. The preparation method is suitable for large-scale industrial production.
Mental health professional helpers including psychiatrists, nurses, psychologists, social workers and occupational therapists often call upon to maintain a good working attitude and enthusiasm, especially in the face of the evaluators of credential systems as well as supervisors' authorities. The symptoms of work-related stress of professional helpers developed day by days and affected their physical and mental health. Gradually, the professional helpers burned out. Philip Burnard (1991) mentioned professional helpers might self-neglect while helping others. These would lead to over work related stress that directly affects the physical and mental health of the professional helpers, and indirectly affects the organization to take care of the patients and their families.

According to researchers and personal experience, colleagues of mental health care developed work-related stress symptoms, such as insomnia or sleep disorder, the physiological disorders, weight fluctuations, irritable or depressed while taking care of psychiatric patients. They might take tranquilizers in order to maintain the quality of work. On the other hand, in April 2012, the researchers engaged in yoga teaching, assisting mental health care to help others of engaging in yoga practice showed that members perceived positive feelings after the yoga practice: "the mood is more relaxed," "tight body become more relaxed and soft resulting in awareness of tension and unease. This helps to modify long-term adverse stances and reduce body aches and/or sitting." For this reason, researchers began to apply yoga to the release work-related stress and enhance stress adaptation. Professional health helpers look forward to practice yoga exercises to relax work-related stress and improve stress adaptation.

It is a parallel-arm randomized control trial compare the outcome of participants assign to the experimental treatment group (yoga, with 30 participants) with those assign to a control group for 3 months (12 weeks). Experimental group receive regular 60-minutes yoga classes twice a week. We confer the difference of work-related stress relief and stress adaptation and biofeedback improvement after yoga.
ETHNOPHARMACOLOGICAL RELEVANCE: Yiqitongmai decoction (YQTMD), a classic TCM, has been widely used in clinical treatment for MI. However, it is still difficult to clarify the potential active compounds and pharmacological mechanisms of it in treating MI.
AIM OF THE STUDY: To explore the active ingredients, pharmacological effects, potential targets and mechanisms of YQTMD against MI.
MATERIALS AND METHODS: Serum pharmacochemistry by UPLC-MS/MS was applied to analyze the phytochemical components in serum from YQTMD. These components were then used to predict the potential targets using network pharmacology approach and molecular dynamics simulations, and then the protective effect of them on H9c2 cells following hypoxic conditions was assessed. Afterwards, the pharmacological effects of YQTMD on MI in mice were tested by determining electrocardiogram (ECG), echocardiography, cardiac biomarkers, oxidative stress, inflammation and pathophysiological changes. The protein levels involving STAT3 signal were detected using Western blot and immunofluorescence assays. Furthermore, STAT3 inhibitor Sttatic was employed to further elucidate the underlying mechanisms.
RESULTS: Totally, 26 compounds derived from YQTMD were identified in mice serum, and 201 genes associated with the compounds were collected. The compounds including safflomin A, ferulic acid, gypenoside XVII, ginsenoside Rg1 and glycyrrhizic acid were identified as the critical compounds of YQTMD to regulate STAT3 pathway. In vitro, compounds combination significantly enhanced the viability of H9c2 cells and reduced ROS level compared to model cells. The in vivo results showed that YQTMD effectively reduced myocardial injury, as evidenced by the decreased serum cardiac injury markers, reduction in the size of myocardial infarct, restoration of abnormal alterations in ECG and decrease in cardiomyocyte apoptosis. Additionally, YQTMD attenuated MI-induced cardiac dysfunction, alleviated pathological changes, reduced MDA levels, and enhanced SOD and GSH levels compared with model mice. Significantly, the levels of IL-6, IL-1β, and TNF-α were observed to decrease in the YQTMD group. The expression levels of key proteins (p-STAT3, HIF-1α, NOX2, TLR5 and Caspase3) in STAT3 pathway were also regulated by YQTMD. However, the cardioprotective effects of YQTMD on MI were attenuated by STAT3 inhibitor Sttatic.
CONCLUSIONS: This study investigated the active ingredients and potential mechanisms of YQTMD for MI treatment based on serum pharmacochemistry and network pharmacology approaches, revealing that YQTMD exerts its therapeutic effects on MI by alleviating oxidative stress, inflammation and apoptosis through adjusting STAT3 signaling pathway.
PURPOSE:To obtain easily the titled highly active pharmaceutical, suitable particularly for vascular obstruction therapy and puncture or centesis method of cancers, and having performance as an obstructive agent, by fixing an anticancer substance and a blood coagulant in a structure containing a neutralized and oxidized cellulose as a material. CONSTITUTION:An anticancer substance and a blood coagulant are fixed in a structure containing a neutralized and oxidized cellulose as a material, e.g. fiber assembly or sponge, by the physical adsorption or entrapping method, etc. to give the titled pharmaceutical having improved sustained release property. The degree of neutralization is preferably such that the neutralized and oxidized cellulose is dipped in water to give 5-6pH. A combination of blood coagulation factor VIII and thrombin is particularly preferred for the blood coagulant. Thus, the vascular therapy can be rapidly and accurately carried out, and the chemotherapy can be carried out in parallel.
The invention discloses a traditional Chinese medicine for treating bad cold, belonging to a medical preparation. The traditional Chinese medicine is prepared from the following medicinal materials in parts by weight of 200 parts of alternanthera nodiflora, 50 parts of yerbadetajo herba ecliptae, 100 parts of cocklebur fruit, 40 parts of folium isatidis, 50 parts of folia perillae acutae and 50 parts of evodia lepta. A preparation method of the traditional Chinese medicine comprises the steps of: preparing for the six medicinal materials of the alternanthera nodiflora, the yerbadetajo herba ecliptae, the cocklebur fruit, the folium isatidis, the folia perillae acutae and the evodia lepta; respectively cleaning, drying by using hot air, disinfecting by using ultraviolet rays, then grinding into 60-mesh powder, uniformly mixing according to the weight proportion of the medicinal materials, and preparing into a tablet according to a conventional pharmaceutical preparation technology, wherein the weight of the medicinal materials in each tablet is 2g. The traditional Chinese medicine has the functions of clearing heat and purging fire, promoting urination and clearing dampness, and diminishing inflammation and expelling toxins, and has a remarkable effect on patients which are suffering from bad cold, and are not treated by existing common Chinese and western medicines. The variety of medicines for treating the bad cold is increased, and the traditional Chinese medicine is used for servicing for the patients. The traditional Chinese medicine is suitable for treating the bad cold.
PURPOSE: A cosmetic composition for hair containing natural dye ingredients is provided to enhance hair and scalp safety and convenience. CONSTITUTION: A cosmetic composition for hair contains Mucuna extract, low molecular phenols, and water soluble metal compounds. The Mucuna extract and low molecular phenols are used as a chromogenic agent. The water soluble metal compounds are used as a mordant. The Mucuna extract is isolated from Mucuna pruriens seeds. The low molecular phenols are gallic acid, salicylic acid, catechin, catechol, vanillin, vanillic acid, ferulic acid, or syringic acid. The cosmetic composition is manufactured in the form of a hair tonic, hair nutrition lotion, hair essence, hair serum, scalp treatment, hair treatment, hair conditioner, hair shampoo, hair lotion, or hair dye.
N-Acetyl Cysteine (NAC) is a compound that increases the levels of Glutathione, the body's main antioxidant. Glutathione is a compound in the blood that is part of a natural defense system (the antioxidant system). Anti-oxidants protect the body from damage caused by internal toxins called free radicals. It is possible that children with Autism tend to have lower levels of glutathione, an important compound in our bodies that helps combat the effects of toxic free radicals. We hope that by studying the antioxidant system in more detail, we will increase our understanding of the reasons why people develop Autism so that we can design better ways to treat individuals with this condition. This study is meant to test the safety tolerability of N-Acetyl Cysteine and its effectiveness in the treatment of behavioral difficulties in children with autism. It will also examine the possible benefit of this agent in improving the core deficits in autism such as social deficits.
PURPOSE: A hair composition containing butyl glycerin ether is provided to ensure soft and smooth texture of hair and resistance against microorganisms. CONSTITUTION: A hair composition contains butyl glycerin ether of chemical formula 1. The butyl glycerin ether has moisturizing and antibacterial effect. The hair composition contains 1-30 wt% of surfactant, 1-10 wt% of moisturizing agent, 1-10 wt5 of higher fatty alcohol, 1-10 wt% of oil, and remaining amount of water. The surfactant is non-ionic surfactant, cationic surfactant, anionic surfactant, positive surfactant, or mixture thereof. The hair composition is manufactured in the form of a shampoo, hair conditioner, hair treatment, hair tonic, hair cream, hair spray, or hair mousse.
Laboratory Test Interference

At room temperature, Elitek causes enzymatic degradation of the uric acid in blood/plasma/serum samples potentially resulting in spuriously low plasma uric acid assay readings. The following special sample handling procedure must be followed to avoid ex vivo uric acid degradation.

Uric acid must be analyzed in plasma. Blood must be collected into prechilled tubes containing heparin anticoagulant. Immediately immerse plasma samples for uric acid measurement in an ice water bath. Plasma samples must be prepared by centrifugation in a precooled centrifuge (4°C). Finally, the plasma must be maintained in an ice water bath and analyzed for uric acid within four hours of collection [see Boxed Warning].

Rasburicase does not metabolize allopurinol, cytarabine, methylprednisolone, methotrexate, 6-mercaptopurine, thioguanine, etoposide, daunorubicin, cyclophosphamide or vincristine in vitro. No metabolic-based drug interactions are therefore anticipated with these agents in patients.
PURPOSE:To obtain the subject composition giving excellent feeling in use and after use by compounding a surfactant based on an ethylene oxide adduct of a polypropylene glycol with a nonionic surfactant based on another alkylene oxide adduct. CONSTITUTION:This make up cosmetic is composed of a surfactant based on an ethylene oxide adduct of a polyethylene glycol having a basic structure of formula I [(e) and (c) are each an integer] and a nonionic surfactant based on another alkylene oxide adduct. As a compound of formula I, a compound of formula II [(a)+(c)=5-200; (b)=5-100] and further a compound of formula III (a content of the ethylene oxide in molecule is 20-70%) are especially preferable. Further, as the above-mentioned nonionic surfactant, an ethylene oxide adduct of hardened castor oil is preferable and a preferable compounding ratio is 0.01-0.5wt.%. Further, the compound of formula I is preferably compounded in an amount of 1-10wt.%. This composition is especially suitable for wiping off lipstick.
Muscle-preserving selective laminectomy with a posterior midline incision and dissection through the nuchal fascia. The spinous processes are split in the midline using a high-speed burr/ultrasound knife and without disturbing the deep extensor muscles on either side. Angulating away from the midline, the spinous processes are divided at their bases. Laminectomy is performed with a width no more than 2-3 mm wider than the dural borders. The facet joints are not exposed. Finally, the split spionous processes are sutured together. No collar or restrictions will be used in either group.
Hard capsules of two strengths, 10 mg and 75 mg of CTH120 to be administered with 200 mL of water. CTH120 will be supplied by CONNECTA Therapeutics. Within each dose cohort group subjects (n=8) will be randomly assigned to the CTH120 dose or to the matching placebo in a 6 to 2 randomization ratio (placebo=2 and CTH120=6 per dose).
OBJECTIVE: An intact cochlear nerve is necessary for successful cochlear implantation (CI). Although the promontory stimulation test (PST) using a promontory stimulator (PS) and a transtympanic needle electrode is invasive, it is still commonly used to verify cochlear nerve function. PSs are currently unavailable because they are no longer manufactured; however, considering that PST continues to be beneficial in certain situations, alternative equipment is needed. The PNS-7000® (PNS) was developed as a neurologic instrument for stimulating the peripheral nerves. This study investigated the usefulness of the ear canal stimulation test (ECST) using PNS with a silver ball ear canal electrode, which is a new noninvasive alternative technique to the PST.
METHODS: ECST was performed from November 2013 to December 2018 using PS and PNS for patients with severe to profound sensorineural hearing loss. The electrical threshold, most comfortable loudness level, uncomfortable loudness level, dynamic range, and gap detection were measured in the ECST. The results of these measured PNS items were compared with PS.
RESULTS: ECST was performed in 61 ears of 35 patients (age, 59.9 ± 20.1 years) using PS and PNS. The sound sensation was elicited in 51 (83.6%) and 52 (85.2%) ears with PS and PNS, respectively. All items excluding GAP were measured in 46 (75%) and 43 (70%) ears at 50 and 100 Hz, respectively. GAP was measured in 33 ears by the ascending and descending methods using PS and PNS. Spearman's rank-order correlation coefficient revealed a significant positive linear correlation between the PS and PNS results in all measurements. No significant difference was found between the PS and PNS thresholds in all measured items.
CONCLUSIONS: PNS is a useful instrument for performing ECST as a new alternative to PS. ECST using a silver ball electrode is a less invasive and easier test than PST.
Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.